BiondVax to Present at Biotech Showcase 2023
January 05, 2023 07:00 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...
BiondVax CEO Issues Letter to Shareholders
December 30, 2022 07:30 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing...
BiondVax Announces Closing of $8 Million Underwritten Public Offering
December 20, 2022 12:42 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)(“Company”), a biotechnology company, which focuses on developing, manufacturing, and...
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
December 16, 2022 08:48 ET
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“Company”), which focuses on developing, manufacturing, and commercializing innovative...